Nilutamide
- Generic Name
- Nilutamide
- Brand Names
- Anandron, Nilandron
- Drug Type
- Small Molecule
- Chemical Formula
- C12H10F3N3O4
- CAS Number
- 63612-50-0
- Unique Ingredient Identifier
- 51G6I8B902
- Background
Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate the g...
- Indication
用于已转移的前列腺癌，可与手术或化学去势合用。
- Associated Conditions
- Metastatic Prostate Cancer
- Associated Therapies
- -
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
- Conditions
- Interventions
- Drug: AbirateroneDrug: BicalutamideDrug: DegarelixDrug: FlutamideDrug: DocetaxelDrug: Goserelin AcetateDrug: Histrelin AcetateDrug: Leuprolide AcetateDrug: NilutamideProcedure: OrchiectomyOther: Quality-of-Life AssessmentRadiation: Radiation TherapyDrug: PrednisoneProcedure: Radical ProstatectomyDrug: Triptorelin
- First Posted Date
- 2018-09-19
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 1273
- Registration Number
- NCT03678025
- Locations
- 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Parkland Memorial Hospital, Dallas, Texas, United States
🇺🇸UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States
Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery
- Conditions
- Interventions
- First Posted Date
- 2017-03-06
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 612
- Registration Number
- NCT03070886
- Locations
- 🇺🇸
Kaiser Permanente Sacramento Medical Center, Sacramento, California, United States
🇺🇸Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
🇺🇸MyMichigan Medical Center Saginaw, Saginaw, Michigan, United States
Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-02-07
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 310
- Registration Number
- NCT01786265
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer
- First Posted Date
- 2009-06-11
- Last Posted Date
- 2014-10-29
- Lead Sponsor
- Duke University
- Target Recruit Count
- 57
- Registration Number
- NCT00918385
- Locations
- 🇺🇸
Oregon Health and Science University, Portland, Oregon, United States
🇺🇸University of Washington/Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer
- First Posted Date
- 2007-08-08
- Last Posted Date
- 2013-01-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT00512668
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-04-03
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 361
- Registration Number
- NCT00002633
- Locations
- 🇨🇦
QEII Health Sciences Center, Halifax, Nova Scotia, Canada
🇨🇦Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦Cancer Centre of Southeastern Ontario at Kingston, Kingston, Ontario, Canada
S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-07-16
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 41
- Registration Number
- NCT00028769
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸CCOP - Atlanta Regional, Atlanta, Georgia, United States
🇺🇸CCOP - Central Illinois, Decatur, Illinois, United States
Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2021-06-23
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 1386
- Registration Number
- NCT00003653
- Locations
- 🇨🇦
BCCA - Cancer Centre for the Southern Interior, Kelowna, British Columbia, Canada
🇨🇦BCCA - Fraser Valley Cancer Centre, Surrey, British Columbia, Canada
🇨🇦Clinical Research Unit at Vancouver Coastal, Vancouver, British Columbia, Canada
Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 306
- Registration Number
- NCT00002855
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-04-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00020254
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.